On Monday, Shares of Vodafone Group Public Limited Company (NASDAQ:VOD), lost -1.43% to $36.51.
Britain’s Vodafone posted a rise in quarterly sales for the first time in nearly three years on Tuesday in the clearest sign yet that Europe’s mobile market is edging towards recovery. according to Reuters.
The world’s second largest mobile operator has been hit hard by the constraints on consumer spending in its big European markets, fierce competition in India and by regulator-imposed price cuts around the world.
But on Tuesday it finally forecast 2016 core earnings growth on an organic basis following seven straight years of declines. Reuters Reports.
Vodafone Group Plc operates as a telecommunications company worldwide. It offers voice, messaging, data, and fixed broadband services; unified communication solutions; Vodafone One Net, a converged service, which combines fixed and mobile services for various businesses.
Shares of 3D Systems Corporation (NYSE:DDD), inclined 6.84% to $22.79, during its last trading session.
3D Systems Corporation, declared a new cooperative R&D agreement with Naval Sea Systems Command’s (NAVSEA) Naval Surface Warfare Center Carderock Division (NSWCCD). In accordance with this agreement, 3DS and the US Navy will jointly develop and evaluate 3D printing technology and materials for military uses, counting assisting the Navy fulfill a number of planned initiatives. The US Navy’s partnership with 3DS underscores the disruptive potential of 3D printing to redefine the supply chain for naval ship components, and reinforces 3DS’ ability to continue to modernize the U.S. defense industrial base.
Development and qualification of new materials and printer technology under this agreement will assist ensure appropriate adoption of this technology within the Navy supply chain.
3D Systems Corporation, through its auxiliaries, operates as a provider of 3D printing centric design-to-manufacturing solutions in the Americas, Germany, and the Asia-Pacific, in addition to other European, the Middle East, and African countries.
At the end of Monday’s trade, Shares of DryShips, Inc. (NASDAQ:DRYS), gained 1.56% to $0.79.
DryShips, declared that in connection with the formerly declared Omnibus Agreement with ENI Angola S.p.A (hereafter referred to as “ENI”), all closing conditions counting approvals by national authorities and signing of definitive documentation have been satisfied.
As a result Ocean Rig has extended the contract for the drillship Ocean Rig Poseidon for a further one year until the second quarter of 2017 with total contract backlog now standing at about $367 million. In addition, Ocean Rig has reached a new contract for the drillship Ocean Rig Olympia to drill offshore Angola commencing in the third quarter of 2015 for a minimum of 8 months with a total contract backlog of about $91 million.
DryShips Inc. provides ocean transportation services for drybulk and petroleum cargoes, and offshore deepwater drilling services. The company operates through Drybulk, Tanker, and Drilling segments. The Drybulk segment provides drybulk commodities transportation services for the steel, electric utility, construction, and agri-food industries. The Drilling segment offers ultra deep water drilling services.
Finally, Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), ended its last trade with 12.37% gain, and closed at $3.36.
Idera Pharmaceuticals, declared the achievement of key development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors (TLRs) 7, 8 and 9. Specifically, the company recently stated top-line data from a Phase 1 clinical trial of IMO-9200 in healthy subjects and declared the presentation of new preclinical data for IMO-9200 in models of inflammatory bowel disease (IBD) at the 2015 Digestive Disease Week Conference (DDW) in Washington, DC.
In the placebo-controlled Phase 1 clinical trial in 30 healthy subjects, IMO-9200 was administered by subcutaneous injection at escalating single-dose levels of 0.1, 0.3, and 0.5 mg/kg. In the multiple dose cohort, a dose of 0.5 mg/kg/week for four weeks was also evaluated. All dose regimens were well tolerated, with no serious adverse events related to IMO-9200 treatment stated. There were no patterns of laboratory or other safety parameters suggestive of any related adverse treatment effect.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
